City of Hope™

A Comprehensive Approach

2009 Annual Report



The Core of our Comprehensive Cancer Center

At City of Hope, thousands of professionals make it their personal mission to fight life-threatening diseases every day. From clinics to classrooms, scientists and medical experts unite to make progress against cancer, diabetes, HIV/AIDS and other serious conditions.

It takes an inclusive strategy to battle a complex condition like cancer. Each type of cancer is different, and each tumor is unique to each individual. Beating the disease requires a team that covers the field, from molecular biologists and laboratory technicians to oncologists, nurses and community educators.

City of Hope knows what it takes to better detect, treat and prevent cancer: It means bringing together the best people, resources and ideas. This is what puts the "comprehensive" in City of Hope's comprehensive cancer center — and what drives the men and women at City of Hope to keep striving for more.

Leadership Message



Terry R. Peets
(right)

Michael A. Friedman, M.D.
(far right)

We often hear firsthand how much City of Hope means to people.

For patients, caregivers and their family members, City of Hope is an ally against disease. To them, it is a medical center where the most highly regarded physicians, nurses and other health professionals combine clinical excellence with deeply ingrained compassion.

Longtime supporters and volunteers view City of Hope as a philanthropic nonprofit that makes a difference in the lives of people across the nation and world through innovative research and new therapies. At the same time, local community members benefit from City of Hope's health education events and outreach. And young future scientists see the institution as a unique training ground where they can learn directly from top researchers through our graduate school.

All of them are right. City of Hope is a medical center, research institute, national charity, educational institution and service organization, and each of these roles is critical to our mission to save lives. These responsibilities all come together under the umbrella of our comprehensive cancer center — a designation granted by the National Cancer Institute to only the most far-reaching research, treatment and educational centers in the country.

In the pages of this report, we invite you to read about how the breadth of the comprehensive cancer center benefits the drive against life-threatening diseases. While the report tells our story through the battle against leukemia, similar interrelated efforts are under way for breast cancer, diabetes, colon cancer and many others. By building on these efforts, we move closer to cures every day.



Terry R. Peets

Chair, Board of Directors
City of Hope



Michael A. Friedman, M.D.

President and Chief Executive Officer
City of Hope

City of Hope Highlights

No. 1

We run the leading prostate cancer and hematologic cancer programs in California.

300

At any given time, we conduct more than 300 clinical trials, with an impressive 25 percent of our patients participating — far more than the national average of less than 5 percent.

$59 MILLION

We were awarded more than $59 million in research grants and received nearly $190 million in revenues from patented technologies in 2009.

21

City of Hope is a founding member of the National Comprehensive Cancer Network, an alliance of 21 leading cancer centers that defines and sets standards for cancer care nationally.

Ranked

ONE OF AMERICA'S BEST
In Cancer and Urology by
U.S.News & World Report

1:40

City of Hope is one of only 40 National Cancer Institute-designated comprehensive cancer centers in the United States.

A Comprehensive Cancer Center: Advances + Advantages

Some research hospitals specialize in basic science. Others test new drugs or study how to prevent disease. But few specialize in all of these — and even fewer integrate these elements to lead the fight against cancer nationally and around the world.

Only those with close links among research, clinical care, education and outreach earn the title of "comprehensive cancer center." From unraveling cancer's molecular origins to improving long-term survival, City of Hope has evolved into a comprehensive health, research and educational center focused on rapidly translating discoveries from science into medicine.

A Rigorous Challenge

Only the National Cancer Institute (NCI), part of the National Institutes of Health, can designate an institution as one of its cancer centers. And among these centers, only a select few meet the criteria of a comprehensive center.

This designation plays out in City of Hope's labs and clinics every day. Some of City of Hope's scientists conduct groundbreaking research on disease mechanisms, stripping cancer of its mysteries. Others translate these discoveries into treatment strategies, launching innovative clinical trials of investigational therapies. Physicians participate in large-scale studies so they can share the benefits of more effective, less toxic treatments with patients as soon as possible.

Leading doctors also collaborate with partners at other research and clinical centers to update treatment standards and improve outcomes. City of Hope reaches out to the public, too, keeping community members up to date on cancer prevention and early detection.

The benefits of care at a comprehensive cancer center are simple: Patients receive treatment plans based on research breakthroughs and participate in trials of the latest investigational therapies. Studies show that outcomes are better at NCI-designated centers. Patients fare better after surgery and they have greater access to palliative care, easing the cancer journey.

Advantages reach beyond cancer. Some of the risk factors for one disease may link to others. For example, some of the causes underlying malignancy risk are also associated with diabetes. Discoveries and lessons learned from cancer research may lead to therapies for HIV/AIDS, neurologic disorders and more.

In this report, we take one type of cancer, leukemia, to tell the story of how all the parts of City of Hope's comprehensive cancer center come together to influence the fight against cancer. In this disease — as in breast cancer, prostate cancer or any of the dozens of other cancers studied and treated at City of Hope — all parts of the cancer center come together for the most important mission: saving people's lives.

City of Hope's Cancer Center Programs

Basic studies
>Cancer Biology Program

Clinical service, research and education
>Cancer Control and Population Sciences Program

Novel therapeutics
>Cancer Immunotherapeutics Program

Molecularly targeted cancer therapeutics
>Developmental Cancer Therapeutics Program

Basic, translational and clinical research
>Hematologic Malignancies Program



Giving Hope to Those Affected by Leukemia


DNA
BASIC SCIENCE
CML patient MNC

Takahiro Maeda, M.D., Ph.D.
Assistant Professor, Stem Cell and Leukemia Research (right)

Ya-Huei Kuo, Ph.D.
Assistant Professor, Stem Cell and Leukemia Research (far right)





Basic Science, Essential Discoveries

Before researchers can create medications to fight cancer, they must understand how the disease grows and develops. So it is with leukemia, a group of blood-based cancers.

Leukemia begins when the DNA in certain blood cells mutates. These changes cause cells to grow abnormally.

The disease can be acute or chronic. In acute leukemia, immature cells called blasts multiply rapidly. These cells crowd out normal blood cells, quickly causing illness. Chronic leukemia is a disease of more mature blood cells. They grow more slowly than in acute leukemia and can function close to normally, at least for a while.

Leukemia can happen in lymphoid cells, which make up lymphatic tissue, or in myeloid cells, the precursors to red and white blood cells and platelets.

Scientists believe leukemia may trace its origins to stem cells, primitive cells that can renew themselves and produce other specialized types of cells. In leukemia, these stem cells go awry. City of Hope's Ravi Bhatia, M.D., not only conducts key studies in his lab on the nature of stem cells, but also leads team efforts through the Division of Hematopoietic Stem Cell and Leukemia Research. Potential new therapies could come from the work.

Clues Within Cells

Acute myeloid leukemia, or AML, is aggressive and difficult to treat. Today, fewer than 23 percent of patients survive five years after diagnosis, and the challenge appears to lie within cancer stem cells.

Traditional chemotherapies kill cells that are actively dividing, a characteristic of cancer cells. But cancer stem cells lurk dormant, allowing them to withstand anticancer drugs — only to awaken and unleash disease again later. It is no wonder City of Hope's Ya-Huei Kuo, Ph.D., assistant professor in the Division of Stem Cell and Leukemia Research, likens them to seeds of cancerous weeds.

Kuo aims to shed light on these stem cells in the lab. In some AML stem cells, two sections of chromosome 16 have switched places, and Kuo has developed a mouse model with this same genetic error. The inversion generates an abnormal protein that hampers the stem cells' ability to produce normal blood cells. Kuo searches for what fuels these cells.

Division colleague Takahiro Maeda, M.D., Ph.D., assistant professor, studies how expression of certain potential oncogenes may turn healthy stem cells into leukemia stem cells. One of these potential oncogenes, leukemia/lymphoma related factor, or LRF, normally manages healthy blood cell formation. When LRF is mutated, though, it can encourage cancer, something Maeda is studying in his own model.

Through the collaborative strength of a comprehensive cancer center, Bhatia, Maeda, Kuo and their colleagues aim to partner with other researchers to translate findings into new therapies.

Basic Science Highlights

Synthetic human insulin was developed through City of Hope research.

Breakthrough cancer drugs Herceptin, Rituxan, Avastin and Erbitux were developed using technology pioneered at City of Hope.

The Center for Biomedicine & Genetics is a groundbreaking model that speeds the translation of research innovations from the lab to the clinic.


TREATMENT

Jeffrey Y.C. Wong, M.D.
Chair and Professor,
Radiation Oncology



New Treatment Strategies Expand Options

Because leukemia has so many forms, physicians can offer no single, standard treatment. Sometimes the disease resists therapy right from the start; sometimes it appears to be defeated, only to return a few years later.

Leukemia treatment usually involves initial chemotherapy to destroy cancerous cells — sending the leukemia into remission — followed by more chemotherapy. Radiation therapy may be needed. Sometimes, if leukemia has returned or is likely to return, a hematopoietic cell transplant (HCT) is the best option.

In HCT, physicians prescribe cancer-fighting drugs and radiation covering nearly the whole body to wipe out the diseased bone marrow and immune system. Then, healthy blood stem cells, collected either from another healthy donor or from the patient before treatment, are infused back into the patient. The stem cells spawn a new, cancer-fighting immune system. City of Hope is a longtime pioneer in many areas of HCT; Stephen J. Forman, M.D., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, is a world-renowned leader in HCT research and treatment. His program, one of the world's largest, is nearing its 10,000th successful transplant.

Unfortunately, many leukemia patients cannot withstand the side effects of the procedure's radiation therapy. But City of Hope radiation oncologists are finely tuning the therapy to extend HCT to many patients previously considered inappropriate for this treatment.

Precise, Powerful Focus

A team of researchers from the Radiation Oncology and Hematology & Hematopoietic Cell Transplantation departments is using imaging to focus radiation where it is most needed. Using the TomoTherapy HI-ART System, physicians led by Jeffrey Wong, M.D., chair of the Department of Radiation Oncology, can now "sculpt" radiation in three dimensions to match the patient's bone marrow precisely. This allows them to potentially use higher doses on diseased tissue while reducing radiation to healthy tissue, decreasing side effects. More than 100 patients, including many with advanced leukemia, already have received the new treatment, called total marrow irradiation.

Researchers are also testing total marrow irradiation with less intensive chemotherapy in clinical trials, potentially making transplantation even more feasible for older, more sensitive patients. Their advances might help leukemia patients in greatest need: those whose disease failed to respond to other treatment or returned and those who cannot tolerate standard regimens.

And they are not alone in reaching more patients. City of Hope's Arti Hurria, M.D., associate professor of medical oncology, and a gerontologic oncologist, is leading the creation of standardized ways to assess older patients with cancer. Some elderly cancer patients appear to be significantly better able to withstand chemotherapy than others, and her research may help bring beneficial therapies to countless older patients once thought poor candidates for treatment.

Treatment Highlights

City of Hope is a national leader in robotic-assisted laparoscopic prostate surgeries. Medical center surgeons have performed more than 4,000 robotic prostatectomies since 2003.

Nearly 10,000 bone marrow transplants have offered a new chance at life to patients from around the world.

City of Hope radiation oncologists were the first in the nation to use TomoTherapy for total marrow irradiation.


CLINICAL RESEARCH

Ravi Bhatia, M.D.
Director, Stem Cell and
Leukemia Research

Moving from Treatment to Cure

Comprehensive cancer centers are wellsprings of discovery, treatment and education. Clinical research brings all these elements together: Basic science breakthroughs lead to investigational treatments that can be rapidly tested in a structured setting where patients receive the highest standards of care.

City of Hope regularly hosts clinical trials of the newest cancer therapies. These treatments are not available outside of a handful of collaborating cancer centers. Some initiated by City of Hope investigators are unavailable elsewhere. An impressive 25 percent of City of Hope patients are enrolled in a clinical trial — far more than the national average of less than 5 percent.

One life-changing product of clinical trials is Gleevec. Unlike earlier cancer drugs that work by killing rapidly dividing cells — healthy cells as well as cancerous ones — Gleevec revolutionized leukemia treatment by shutting off proteins the cancerous cells need to grow and multiply. Taking Gleevec every day can keep chronic myeloid leukemia (CML) at bay. But leukemia stem cells may eventually grow resistant to the drug, spawning more aggressive leukemia cells. Now, City of Hope researchers are striving to make Gleevec even more potent by pairing it with new drugs created using insights from epigenetics.

Reactivating Good Genes

A relatively young field with early connections to City of Hope, epigenetics focuses on changes in the way genes are expressed, without altering their underlying DNA sequence. Cells can turn their genes on and off by tagging sections of their chromosomes; but when the process goes awry, these changes can promote cancer if a switched-off gene is one that normally protects the body from disease. Fortunately, the process can be reversed.

New leukemia-fighting agents include classes of epigenetic drugs that can reactivate protective genes, such as histone deacetylase (HDAC) inhibitors. HDAC inhibitors stop enzymes that make chromosomes coil up tightly. By allowing the chromosomes to relax, the new drugs can switch anticancer genes back on, slowing the progress of disease.

The laboratory of Ravi Bhatia, M.D., already has shown success in the use of an HDAC inhibitor paired with Gleevec. Bhatia leads clinical trials combining Gleevec and panobinostat against CML. This one-two punch appears to knock out active leukemia cells and diseased stem cells, possibly preventing relapse. A new clinical trial will see whether the combination can keep CML patients with a particularly aggressive form of the disease in remission.

As a National Cancer Institute-funded comprehensive cancer center, City of Hope helps brings science from the lab into the clinic, speeding potential new treatments safely to patients around the nation and world.

Clinical Research Highlights

City of Hope scientists are the first to conduct a clinical trial testing T cells engineered to seek out and attack glioma, a deadly brain cancer.

Studies of epigenetic drugs may lead to powerful treatments meant to fight the cancer stem cells that spur recurrence of chronic myelogenous leukemia and other cancers.


POPULATION STUDIES

Saro Armenian, D.O., M.P.H.
Medical Director,
Pediatric Survivorship Clinic,
Childhood Cancer Survivorship
Program (right)

Smita Bhatia, M.D., M.P.H.
Associate Director for Population
Research, Comprehensive Cancer
Center (far right)

Combating Late Effects

More than 350,000 long-term survivors of childhood cancers are alive in the U.S. today. Unfortunately, the very therapies that saved their lives may cause long-term complications as they grow up. These "late effects" range from growth delays to reproductive problems. Some leukemia patients develop second cancers related to treatment.

Researchers at City of Hope's comprehensive cancer center are world leaders in understanding late effects. Smita Bhatia, M.D., M.P.H., director of the Center for Cancer Survivorship and chair of the Department of Population Sciences, leads a team studying thousands of cancer cases for causes, genetic factors and intervention strategies that may help prevent long-term problems. At the same time, the team monitors individual patients, often for decades after treatment.

Among their challenges is lymphoma, because its treatment causes certain patients to develop acute myeloid leukemia later. Bhatia's team looks for genetic reasons why only some are susceptible. These insights could lead to ways to identify patients likely to develop a second cancer, so that doctors could tailor their therapies to reduce risk in these patients. The findings might also help explain how certain genes promote cancer in the first place, leading to new treatments.

Healing Hearts

Many patients with leukemia and other cancers are treated with anthracyclines, tumor-fighting antibiotics, but high doses of these drugs can damage the heart and lead to congestive heart failure.

Saro Armenian, D.O., M.P.H., medical director of the Childhood Cancer Survivorship Program, is leading the most wide-ranging study ever conducted of heart failure in hematopoietic cell transplant (HCT) survivors. His team already has identified a way to protect childhood cancer survivors using a common heart drug. Researchers are testing the drug in 160 City of Hope HCT patients; if results are positive, it could help protect countless patients.

Such studies are a natural extension of City of Hope's leadership role in developing national standards for follow-up care and its deep involvement in large-scale survivorship studies. City of Hope researchers head a national network to track patients at more than 200 centers belonging to the Children's Oncology Group, an umbrella of institutions treating pediatric cancers. By sharing data, these group members combine their strengths and share important findings far more quickly.

City of Hope physicians are active in prevention, as well. Melanie Palomares, M.D., M.S., associate professor of medical oncology and population sciences, for example, studies how to keep cancer from returning among survivors, as well as how to prevent it in those at high risk. These studies include the evaluation of grape seed extract and mushrooms as chemopreventive tools against breast cancer.

The multidisciplinary strengths of a comprehensive cancer center — combining geneticists, epidemiologists, physicians and other experts — make these advances possible.

Population Studies Highlights

Population studies show that pediatric cancer patients experience lifelong effects, so City of Hope offers a clinic to monitor patients for years after treatment.

City of Hope scientists are narrowing down the genes that contribute to heart disease among childhood cancer survivors. Knowing genetic risk may help head off complications before they start.

Family history can increase a person's cancer risk. City of Hope's *Cancer Screening & Prevention Program*℠ shows people how to minimize risks and stop cancer early on.


OUTREACH/EDUCATION

Defu Zeng, M.D.
Associate Professor, departments of Diabetes and Metabolic Diseases Research and Hematology & Hematopoietic Cell Transplantation

Reaching Out, Reaching Beyond

National Cancer Institute (NCI) funding is public funding, and as an NCI-funded comprehensive cancer center, City of Hope firmly believes in sharing its resources to benefit the community. The institution reaches out by providing community education programs, as well as training and ongoing education for graduate students, postdoctoral trainees, physicians, pharmacists and other health-care professionals. Dozens of nursing students complete their clinical rotations at City of Hope every year, while administrative fellows gain real-world experience in hospital and research operations.

The Department of Continuing Medical Education keeps community physicians up to date on the latest treatments and standards of patient care in leukemia and other cancers through courses, conferences and symposia. In addition, City of Hope works with the American Cancer Society to encourage more underserved minorities to participate in clinical trials.

City of Hope also supports the next generation of cancer specialists through fellowships and residencies. One, the Tim Nesvig Research Fellowship in Lymphoma, encourages the career growth of promising young researchers. In 2009, Defu Zeng, M.D., associate professor in the departments of Diabetes and Metabolic Diseases Research and Hematology & Hematopoietic Cell Transplantation, used his fellowship to pursue a strategy that could make bone marrow transplantation safer by easing a potentially dangerous side effect called graft-versus-host disease (GVHD). Solving the problem of GVHD could extend stem cell transplants to many more patients, potentially including those with autoimmune diseases such as diabetes and multiple sclerosis. Young scientist and postdoctoral fellowship recipient Anna Scuto, Ph.D., of the Department of Molecular Medicine, is pursuing the potential of certain targeted therapies to fight a difficult form of lymphoma.

Awareness, Education and Support

City of Hope advances community health through a network of public and private partnerships. In 2009, for example, City of Hope's Center of Community Alliance for Research & Education and the Department of Clinical Nutrition partnered with the city of Duarte and Duarte Unified School District to offer "Eat, Move, Live," a program for Latino parents covering nutrition, disease prevention, physical activity and food safety.

Through "Ask the Experts" events, City of Hope health experts regularly talk with community members about the latest progress against cancer. Organizations such as The Leukemia & Lymphoma Society, the American Cancer Society and the Wellness Community frequently co-sponsor the events. City of Hope also organizes or offers information at community health fairs throughout the area, sharing vital health knowledge with thousands of visitors.

In addition, City of Hope works with the National Marrow Donor Program registry to facilitate critical marrow and blood stem cell transplants for patients with leukemia and other life-threatening diseases. Volunteer registrants at City of Hope can save lives around the world.

Outreach/ Education Highlights

"I Can Cope" workshops show patients how proper nutrition can help them feel better during and after cancer treatment.

Fellowships in areas of oncology, pathology and endocrinology provide educational opportunities for physicians driven to help those with cancer and diabetes.

The Center of Community Alliance for Research & Education aims to reduce and eliminate inequalities in cancer outcomes among underserved patients and communities.


support


effort


FARMERS


vision


care

Comprehensive Support

City of Hope draws strength from diversity. The mission of curing and preventing life-threatening disease brings together experts from an array of disciplines — from basic science to prevention research. The philanthropy that backs this healing enterprise has similar scope — individual donors, foundations, corporations and volunteer groups united in the battle against cancer, diabetes and other serious illnesses.

In 2009, this team of thousands joined together to contribute more than $107 million to City of Hope. Planned gifts — including annuities, bequests and charitable trusts — garnered more than $26 million, while industry partners' cause-related marketing efforts drew more than $3.6 million.

Milestone events exemplified the importance of support from individual donors. The Michael Amini Transfusion Medicine Center, home to all blood-collection, analysis, processing and transfusion programs, was dedicated in April. The building was made possible through many gifts, including the lead gift from Michael Amini, a longtime member of City of Hope's National Home Furnishings Industry and founder and chief executive officer of Amini Innovations Corporation.

In late 2009, City of Hope marked the opening of the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology. Begun with a 2006 leadership gift of $20 million from the Arnold and Mabel Beckman Foundation, the building houses modern labs for critical research, as well as City of Hope's graduate school.

Graduate education at City of Hope also benefited from the generosity of the law firm Irell & Manella. The firm's $5 million gift, matched by an anonymous $5 million contribution, endowed and named the Irell & Manella Graduate School of Biological Sciences at City of Hope, while an additional $2 million from the firm established the Irell & Manella Visiting Professorship. In addition, the firm contributed $3 million to create the Irell & Manella Cancer Center Director's Distinguished Chair, held by Michael A. Friedman, City of Hope's president, chief executive officer and cancer center director.

Irell & Manella partner Morgan Chu and his wife, Helen, provided $2.5 million to establish another endowed chair, as well: the Morgan and Helen Chu Director's Chair of Beckman Research Institute. Richard Jove, Ph.D., the institute's director and a professor of molecular medicine, became the first holder of the chair.

Other benefactors also built critical endowments. A $3.5 million bequest from the Estate of Liliane Elkins created an endowment fund supporting the Sheri & Les Biller Patient and Family Resource Center and established the Liliane Elkins Professorship in Supportive Care Programs.

Philanthropy Highlights

$107 million was contributed by individuals, volunteer groups, foundations, corporations and auxiliaries in 2009 to support City of Hope.

$10 million in donations — $5 million from the law firm of Irell & Manella and a matching $5 million anonymous gift — helped establish the Irell & Manella Graduate School of Biological Sciences.

$2.5 million established the Morgan and Helen Chu Director's Chair of Beckman Research Institute.

Matthew Loscalzo, L.C.S.W., the center's administrative director and executive director in the Department of Supportive Care Medicine, is the professorship's first holder.

New faculty member and prominent molecular epidemiologist Susan L. Neuhausen, Ph.D., was named the first Morris & Horowitz Families Professor in Cancer Etiology and Outcomes Research. The professorship resulted from a 2008 gift of $1 million from longtime City of Hope supporters Monique and Doug Morris. Doug Morris, chair and chief executive officer of Universal Music Group, and Zach Horowitz, president and chief operating officer of Universal Music Group, each made a contribution in 2009 to supplement the endowment for the professorship.

Major donors also backed important City of Hope landmarks. A $1 million gift from philanthropist Morton La Kretz will fund renovation of the institution's 1940s-era temple, to be called the Morton La Kretz House of Hope.

Laboratory science drew robust support as well. A $1 million gift from a donor who wished to remain anonymous and $540,000 from the American Cancer Society backed basic research at Beckman Research Institute of City of Hope. ThinkCure, the Los Angeles Dodgers' official charity, contributed $550,000 for individual and collaborative studies between City of Hope and Childrens Hospital Los Angeles.

Many donors focused their philanthropy on specific diseases. Sharon and Michael Ensign gave $1 million to continue their support of the Sharon and Michael Ensign Urologic Oncology Fund, while The Leukemia & Lymphoma Society contributed $600,000 to fight hematologic cancers. STOP CANCER supported scientists pursuing brain, breast and pancreatic cancer research as well as immunotherapy investigations with $335,000. Breast cancer research also drew $300,000 in funding from the Avon Foundation. A $300,000 grant from the Ibrahim El-Hefni Technical Training Foundation supported liver cancer research and training fellowships.

Aid from Industry

City of Hope's 21 industry groups continued their tradition of generous support. Music and Entertainment Industry *Spirit of Life*® honoree Tim Leiweke, president and chief executive officer of AEG, led an innovative fundraising initiative that included a successful employee-giving program. In addition, a portion of sales from events such as Los Angeles Kings games and nationwide tours by stars from television's "American Idol" and "So You Think You Can Dance" benefited City of Hope.

The Music and Entertainment Industry also united with the National Office Products Industry (NOPI) for a benefit concert that raised more than $800,000. The second annual Concert for Hope presented by Staples featured Disney Music Group artists Miley Cyrus, Demi Lovato and Jesse McCartney.

$3.5 million established the Liliane Elkins Professorship in Supportive Care Programs.

$550,000 was raised by ThinkCure, the official charity of the Los Angeles Dodgers, which funded collaborative cancer research between City of Hope and Childrens Hospital Los Angeles.

$600,000 donated by The Leukemia & Lymphoma Society supports studies of hematologic cancers.

$800,000 was raised at the 2009 Concert for Hope featuring Miley Cyrus, Demi Lovato and Jesse McCartney.

NOPI honored *Spirit of Life* awardee Jack Truong, Ph.D., vice president of 3M, during its annual initiative for City of Hope. Highlights included a 3M direct-mail gift-matching program supported by public service announcements featuring NASCAR driver Greg Biffle. Product promotions from 3M/Post-it, MWV, Newell Rubbermaid and Staples/Quill bolstered efforts.

In addition, Staples served as national presenting sponsor for Walk for Hope, City of Hope's annual fundraising walk. The 2009 Walk for Hope events, held in nine cities, raised $2.4 million to fight breast cancer. Hilton HHonors, *Ladies' Home Journal* and Pink Channel XM Satellite 24 served as national sponsors.

Industry groups attracted major gifts with impact: Alexandra Real Estate Equities, part of the Los Angeles Real Estate & Construction Industries Council, for one, donated $250,000. City of Hope's food industries groups conducted several successful cause-related programs, such as initiatives by Albertsons, Ralphs and the Safeway Foundation.

Companies also supported City of Hope through media partnerships. City of Hope's message spread to millions of homes when City of Hope became the 2009 official charity of the NFL on FOX — thanks to FOX Sports Supports, the network's on-air charitable initiative. Major League Soccer's Chivas USA partnered with City of Hope to raise diabetes awareness in Southern California. Pink Channel XM Satellite 24, Sky Radio and the Style Network also promoted City of Hope to their audiences.

A History of Generosity

A nationwide network of volunteer chapters and auxiliaries continued building on a legacy of generosity. Many chapter members included the institution in their estate plans. Significant bequests included $1 million from the Estate of Norma Lefkowitz, of the Board of Governors; $600,000 for research into women's cancers from the trust of Jack D. Goldberg and Shirley H. Goldberg, of the Esperanza Chapter; and $270,000 from the trust of Jessie Nehf, of the Dershewitz/Aid for Life Chapter.

Planned gifts from donors are crucial to the institution. Unrestricted support came from the Estate of Edwin J. Horton through a $1.1 million bequest; a $1 million bequest from the trust of Emily R. Koelzer; $500,000 from the trust of Marijan J. and Ingrid K. Markul; and $500,000 from the trust of Dwight A. Newell. The trust of Florence A. Neilan backed research into gastrointestinal cancers with a $500,000 bequest.

A wide spectrum of supporters share City of Hope's mission. Their diverse backgrounds come together behind a common philanthropic vision: helping City of Hope build a world free of serious illness.

Nearly two dozen industry groups have made City of Hope a national fundraising beneficiary, giving millions of dollars to research.

$2.4 million was raised in 2009 by participants in City of Hope's Walk for Hope events.

Fox Sports Supports made City of Hope one of its official charities for 2009, carrying the message of hope to millions of football fans across the U.S.

$26 million was donated in 2009 through planned gifts, including annuities, bequests and charitable trusts, to support City of Hope's lifesaving research and treatment programs.

Acknowledging our Donors

To be the best possible stewards of our supporters' generous donations and to conserve resources, the 2009 Donor List will appear online.

We sincerely thank all of our donors who contributed so much to City of Hope during the past year and who remain committed to helping us prevent and cure cancer, diabetes and other life-threatening diseases. Their support makes possible the life-changing work that takes place every day at City of Hope.

To view the 2009 Donor List please visit our website at www.cityofhope.org/annualreport.

2009 *Spirit of Life*® Honorees

The *Spirit of Life*® Award is the highest honor City of Hope bestows on an individual for his or her philanthropic endeavors. Recognizing a lifetime of personal and professional achievement, the award is presented to an industry, chapter or community leader who, through his or her actions, exemplifies our mission. These individuals share a deep commitment to advancing scientific research that will improve treatment for patients everywhere.

David Blum
aspenhome
National Home Furnishings Industry

Irv Blumkin
Nebraska Furniture Mart
National Home Furnishings Industry

Jeff Child
R.C. Willey Home Furnishings
National Home Furnishings Industry

William Colegrove
aspenhome
National Home Furnishings Industry

Michael Covarrubias
TMG Partners
Northern California Real Estate and Construction Business Alliance

Jena Hall
aspenhome
National Home Furnishings Industry

Dave Heard
aspenhome
National Home Furnishings Industry

Parker S. Kennedy
The First American Corporation
Construction Industries Alliance

Bill Kimbrell
Star Furniture Co.
National Home Furnishings Industry

Hoda Kotb
NBC
East End Chapter

John Langel
Ballard, Spahr, Andrews & Ingersoll
Tri-State Labor & Management Council

Cheryl and Jim Markham
Jim Markham Enterprises
National Professional Salon Industry

Bruce Merino
The Home Depot
Hardware/Homebuilding Industry

Andy Nielsen
aspenhome
National Home Furnishings Industry

William Reece
aspenhome
National Home Furnishings Industry

Jeffrey A. Riemer
Bovis Lend Lease Chicago
Chicago Construction and Real Estate Council

Eli Simsollo and Josef Simsolo
Simso Tex Sublimation Printing
Apparel Industries Group

Eliot Tatelman
Jordan's Furniture Inc.
National Home Furnishings Industry

Dr. Jack Truong
3M
National Office Products Industry

Kay Unger
Kay Unger New York
East End Chapter

James Weidner
Cooperative of American Physicians Inc.
National Insurance Industry Council

Kim Whitlock
aspenhome
National Home Furnishings Industry

Wendell Young
UFCW LU 1776
Tri-State Labor & Management Council

2009 Financials

$1.2
BILLION
2009 net assets

$107.4
MILLION
2009 contributions and
net special event revenues

$322.7
MILLION
2009 royalties and
research grants

$468.5
MILLION
2009 net patient
service revenues

Patient Information

For fiscal years beginning October 1 and ending September 30 (dollar amounts in thousands)	2009	%	2008	%
Charges for Patient Services				
Medicare	$ 359,427	24.9%	$ 331,878	27.2%
Indemnity insurance	13,075	0.9%	7,201	0.6%
Managed care contracts	794,882	55.0%	672,961	55.1%
Subsidized care	276,824	19.2%	209,203	17.1%
Total	$1,444,208	100.0%	$1,221,243	100.0%
Patients Treated (based on admissions)				
New patient referrals	7,535		7,179	
Patients treated during year	22,485		20,960	
Admissions	6,361		6,295	
Patient days	57,258		54,878	
Clinic and infusion visits	136,561		128,830	
Bone marrow transplants (BMT)	620*		608*	

* Includes BMTs performed at the City of Hope-Banner BMT Program. City of Hope and Banner Good Samaritan Medical Center terminated that relationship. This includes BMTs performed up to the termination date of July 1, 2009.

City of Hope and Affiliates
Combined Statements of Financial Position

For fiscal years beginning October 1 and ending September 30 (amounts in thousands)	2009	2008
Assets		
Current Assets		
Cash and cash equivalents	$ 139,477	$ 158,129
Investments	189,005	110,801
Patient accounts receivable, less allowances for uncollectible accounts of $1,699 in 2009 and $930 in 2008	105,079	72,227
Grants and other receivables	18,970	13,348
Donor restricted unconditional promises to give, net	14,109	16,416
Prepaid and other	11,735	13,915
Total current assets	478,375	384,836
Property, Plant and Equipment, net of accumulated depreciation of $368,181 in 2009 and $336,538 in 2008	507,901	426,571
Other Assets		
Investments	12,083	10,384
Board designated investments	434,257	355,963
Bond trust funds	28,799	65,424
Donor restricted assets	161,880	163,082
Other assets	10,211	15,763
Total other assets	647,230	610,616
Total Assets	$1,633,506	$1,422,023
Liabilities and Net Assets		
Current Liabilities		
Accounts payable and accrued liabilities	$ 112,665	$ 102,110
Long-term debt, current portion and accrued interest	11,763	14,727
Total current liabilities	124,428	116,837
Long-term Debt, net of current portion and unamortized discount of $1,745 and $1,871 as of September 30, 2009 and 2008, respectively	263,614	272,085
Annuity and Split-interest Agreement Obligations	19,698	20,140
Other	14,133	10,040
Total liabilities	421,873	419,102
Net Assets		
Unrestricted	1,003,637	798,391
Restricted	207,996	204,530
Total net assets	1,211,633	1,002,921
Total Liabilities and Net Assets	$1,633,506	$1,422,023

City of Hope and Affiliates
Combined Statements of Activities

For fiscal years beginning October 1 and ending September 30 (amounts in thousands)	2009	2008
Revenues		
Net patient service revenues	$ 468,509	$ 423,533
Contributions and net special event revenues	107,361	100,810
Royalties and research grants	322,703	462,679
Other	(8,855)	28,451
Total Revenues	889,718	1,015,473
Expenses		
Program services	615,070	596,838
Supporting services	124,585	102,595
Total expenses	739,655	699,433
Operating income	150,063	316,040
Change in net unrealized gain (loss) on investments	59,410	(51,338)
Loss on interest rate swap agreement	(761)	(587)
Change in net assets	208,712	264,115
Net Assets, beginning of year	1,002,921	738,806
Net Assets, end of year	$1,211,633	$1,002,921

City of Hope and Affiliates
Combined Statements of Cash Flow

For fiscal years beginning October 1 and ending September 30 (amounts in thousands)	2009	2008
Cash Flows from Operating Activities		
Changes in net assets	$208,712	$264,115
Adjustments to reconcile changes in net assets to net cash provided by operating activities:		
Depreciation and amortization	36,931	34,468
Unrealized (gain) loss on investments	(59,410)	51,338
Other changes in operating assets and liabilities	(51,886)	395
Total adjustments	(74,365)	86,201
Net cash provided by operating activities	134,347	350,316
Cash Flows from Investing Activities		
Proceeds from sales of property, plant and equipment	3,304	1,454
Additions to property, plant and equipment	(118,875)	(79,004)
Change in investments	(69,200)	(199,695)
Net cash used in investing activities	(184,771)	(277,245)
Cash Flows from Financing Activities		
Net cash provided by financing activities	31,772	16,039
Net (decrease) increase in cash and cash equivalents	(18,652)	89,110
Cash and cash equivalents, beginning of year	158,129	69,019
Cash and cash equivalents, end of year	$139,477	$158,129

Executive Leadership and Board of Directors

2009 Executive Leadership

Michael A. Friedman, M.D.
President and Chief Executive Officer
Director, Comprehensive Cancer Center
Irell & Manella Cancer Center Director's Distinguished Chair

Debra F. Fields, J.D.
Chief Risk Officer

Richard Jove, Ph.D.
Morgan and Helen Chu Director's Chair of Beckman Research Institute
Deputy Director, Comprehensive Cancer Center

Kathleen L. Kane, J.D.
Executive Vice President, Development and External Affairs

Alexandra M. Levine, M.D., M.A.C.P.
Chief Medical Officer
Deputy Director for Clinical Programs, Comprehensive Cancer Center

Virginia A. Opipare
Executive Vice President and Chief Operating Officer

Robert W. Stone
Chief Strategy and Administrative Officer

Board of Directors

Chair
Terry R. Peets
Sheri J. Biller
(Effective July 1, 2010)

Vice Chair
Sheri J. Biller
Norman C. Payson, M.D.
(Effective July 1, 2010)

Chairs Emeritus
Philip L. Engel
Meyer E. Hersch
Gil N. Schwartzberg
Jack R. Suzar
Richard S. Ziman

General Vice Chair
Ben Horowitz

Board Members
Lynn Beckemeyer
John M. Boushy
(Effective March 5, 2010)
Alexander L. Cappello
Robert A. Cook
L. Dale Crandall
Rodney C. Freeman
Eddy W. Hartenstein
Selwyn Isakow
Michael E. Keane
Jacqueline B. Kosecoff, Ph.D.
Harry Levitt
Thomas A. Madden
Jody Horowitz Marsh
(Effective November 13, 2009)
Kathleen G. McNamara
Robert G. Miller
Gail K. Naughton, Ph.D.
Norman C. Payson, M.D.
Tony E. Scott
Ronald J. Silverman
Ernie C. So
Stephan E. Tow
Stanley E. Washington

Honorary Directors
Israel J. Freeman
Robbin L. Itkin
Michael B. Kaplan
Stephen B. Kass
Sidney L. Kline
Mark B. Levey
Claire L. Rothman
Joseph P. Sanford

Board of Regents

Rhoda K. Ehrlich
Philip L. Engel
Bonnie L. Fein
John T. Frankenheimer, J.D.
Israel J. Freeman
Leon Frieden
Richard D. Gibbs
Robert N. Goodman
Michael Greenberg
Meyer E. Hersch
Zachary I. Horowitz
Louise Horvitz, M.S.W., Psy.D.
Robbin L. Itkin, J.D.
Michael B. Kaplan, J.D.
Stephen B. Kass, J.D.
Sidney L. Kline
Laurie Konheim
Mark B. Levey
Rhoda Makadon
David Z. Marmel
Jack L. Meyers
David Morse
Richard B. Myers
Mark Oliff
Ricky Paskow
Claire L. Rothman
Iris Rothstein
Nina Madden Sabban
Joseph P. Sanford
Clarence T. Schmit
Gil N. Schwartzberg, J.D.
Judge Bernard Selber
Bernard J. Siegel
Andrew Spiegl
Adrienne Ehrlich Stern
Bobbie M. Stern
Jack R. Suzar
Esther A. Torrez
Dan E. Young
Richard S. Ziman

Administrative Leadership and Board of Directors (continued)

Medical Center Board of Directors

Chair
Jacqueline B. Kosecoff, Ph.D.

Mordecai N. Dunst, M.D.
Donald W. Hoffman
Ben Horowitz
Lucille A. Leong, M.D.
Thomas A. Madden
Richard B. Myers
Claire L. Rothman
Iris Rothstein
Ernie C. So
Andrew Spiegl

Beckman Research Institute Board of Directors

Chair
Ernie C. So

Gary E. Freedman
Ben Horowitz
Jacqueline B. Kosecoff, Ph.D.
Harry Levitt
Elliot Rosman
John J. Rossi, Ph.D.
Iris Rothstein

Chairs of the Board

Barnett Cohen
(1913-1920)

Benjamin Forer
(1920-1922)

Dr. Henry Silverberg
(1922-1925)

J.A. Rosenkranz
(1925-1926, 1933-1936, 1939-1941)

Dr. Nahum Kavinoky
(1926-1927)

Chaim Shapiro
(1927-1929)

Dr. Moses I. Devorkin
(1929-1931)

Lester W. Roth
(1931-1933)

Mark Carter
(1936-1939)

Pinches Karl
(1941-1944)

Ben Solnit
(1944-1946)

Louis Tabak
(1946-1949, 1957-1961)

Victor M. Carter
(1949-1957)

Seymour Graff
(1961-1964)

Emanuel H. Fineman
(1964-1971)

Percy Solotoy
(1971-1975)

Meyer E. Hersch
(1975-1983)

Abraham S. Bolsky
(1983-1989)

Richard S. Ziman
(1989-1995)

Gil N. Schwartzberg
(1995-1999)

Jack R. Suzar
(1999-2004)

Philip L. Engel
(2004-2007)

Locations

City of Hope and Beckman Research Institute

1500 East Duarte Road
Duarte, CA 91010-3000
800-423-7119
www.cityofhope.org

City of Hope Development Headquarters

1055 Wilshire Boulevard
Los Angeles, CA 90017
800-544-3541

Regional Development Offices

Southeast
Fort Lauderdale, Fla.
800-584-6709

Midwest
Chicago
800-779-5893

Northeast
Philadelphia
800-344-8169

Southwest
Cathedral City, Calif.
800-732-7121

Orange County, Calif.
800-235-0579

Phoenix
800-732-7309

San Diego
888-805-8911

Northwest
San Francisco
800-732-7140

Seattle
800-934-9196

City of Hope™

1500 East Duarte Road
Duarte, CA 91010
626-256-HOPE (4673)